Clinical Trial Update: Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing the safety of subcutaneously administered gpASIT+ in hay fever patients, with and without an immunoregulating adjuvant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• gpASIT+TM

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Hay Fever | Phase 2 | Status: COMPLETED